Acorda Therapeutics has enrolled the first patient in a trial of AC105, its proprietary magnesium formulation for the treatment of spinal cord injury (SCI). This Phase II trial will evaluate the safety and tolerability of the drug in people with traumatic SCI, and also incorporates several exploratory efficacy measures. The primary objective of the double-blind, randomized and placebo-controlled study is to evaluate the safety and tolerability of AC105 in people who have suffered an SCI. The st...